Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Terminated 3Completed 2

Sponsor Class

OTHER 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Other neoplasm 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Hepatitis C 3Lymphoma, Non-Hodgkin 2Precancerous Conditions 1Melanoma 1Malignant Solid Tumor 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma 1Liver Neoplasms 1Liver Diseases 1Leukemia, Myeloid, Acute 1Infections 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Ribavirin 3tremelimumab 1telaprevir 1peginterferon alfa-2a 1menatetrenone 1ledipasvir, sofosbuvir drug combination 1Sofosbuvir 1Infliximab 1Hypothermia, Induced 1Chromatography, High Pressure Liquid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × Hepatitis C × Ribavirin × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

NCT02717949 2019-01-08

Optimal

University of Texas Southwestern Medical Center

Phase 4 Terminated
1 enrolled
Lymphoid

Hepatitis C, Liver Diseases, Lymphoma, Non-Hodgkin

NCT00897312 2016-04-25

Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease

Vanderbilt-Ingram Cancer Center

Terminated
7 enrolled
DermatologicOther neoplasm

Hepatitis C, Melanoma, Precancerous Conditions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡